Jose-Carlos Segovia, PhD from Universidad Autónoma de Madrid works on the study of hematopoietic stem cells (HSC) and on HSC gene transfer, to develop gene therapy protocols for the treatment of hematopoietic genetic diseases. Currently, he is Head of the Cell Technology Division (CTD) and of the Flow Cytometry and Cell Separation Laboratory (LACISEP), at the Center for Energy, Environmental and Technological Research (CIEMAT), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) e Instituto de Investigación Sanitaria Fundación Jimenez Díaz (IIS-FJD), Madrid, Spain. He has developed the lentiviral gene therapy for Pyruvate Kinase Deficiency and contributed to Fanconi Anemia one, nowadays in successful clinical trials. He is a scientific founder of DanausGT Biotechnology, with the aim to drive gene editing to patients. He has been secretary of the Spanish Society of Gene and Cell Therapy, vice-president of the Iberian Society of Cytometry and nowadays, consultant of the Spanish Agency for Medicine and Sanitary Products.